Rare Biomarkers Specimen Collection And Stabilization Global Market 2024 - Growth Opportunities, Top Countries, Future Trends, Revenue And Outlook 2033

The Business Research Company recently released a comprehensive report on the Global Rare Biomarkers Specimen Collection And Stabilization Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.

Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=15913&type=smp

According to The Business Research Company's, The rare biomarkers specimen collection and stabilization market size has grown rapidly in recent years. It will grow from $29.02 billion in 2023 to $32.01 billion in 2024 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to the human genome project, increase in cancer research, pharmaceutical R&D investment, growth of genomics and proteomics, and improved data management and bioinformatics.

The rare biomarkers specimen collection and stabilization market size is expected to see rapid growth in the next few years. It will grow to $47.59 billion in 2028 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to the expansion of liquid biopsy applications, consumer awareness and demand, increasing adoption of non-invasive techniques, and biomarker discovery in rare diseases. Major trends in the forecast period include advancements in preservation technology, growth in genomic and proteomic research, the emergence of point-of-care testing, and regulatory advancements and standardization, enhanced data analytics, and AI integration.

Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/rare-biomarkers-specimen-collection-and-stabilization-global-market-report

Market Drivers and Trends:

The rise in the prevalence of chronic diseases is expected to propel the growth of the optical microscope market. Chronic disease refers to a health condition or disease that is persistent or long-lasting in its effects, usually lasting for three months or longer, and may get worse over time. Rising chronic diseases are driven by lifestyle factors such as poor diet, lack of exercise, and increased stress. Optical microscopes are used in chronic disease research to observe and analyze cellular and tissue changes. For instance, in January 2023, according to the National Center for Biotechnology Information (NCBI), a US-based international resource for the scientific research community, the projection suggests that by 2050, the number of individuals aged 50 and above with one or more chronic illnesses will nearly double, reaching 142.66 million, up from 71.522 million in 2020. Furthermore, in December 2023, according to the Australian Institute of Health and Welfare (AIHW), an Australia-based government agency, between 2020 and 2021, it was estimated that around 47%, equivalent to 11.6 million individuals, in Australia were impacted by at least one of the selected ten chronic ailments. Therefore, the rise in the prevalence of chronic diseases is driving the growth of the optical microscope market.

Major companies operating in the rare biomarker specimen collection and stabilization market are focusing on developing innovative solutions, such as a pre-analytical platform to automate the preparation of plasma and cell samples for multiomic liquid biopsy. Pre-analytical platform provides consistent, automated fresh sample preparation at the time of blood collection. It allows for complete walk-away processing of whole blood without the need for special tubes or skilled professionals, therefore preserving sample integrity. For instance, in May 2022, Tethis S.p.A., an Italy-based biotechnology company, launched See.d, the first fully automated, standardized pre-analytical platform that offers unique features such as precise sample handling, efficient separation of plasma for cellular fractions, and fixation of white blood cells on SmartBioSurface slides. The platform features a quality control scoring system for objectively evaluating sample stability. This approach enables the systematic scoring of proteomics and metabolomics data sets to determine the stability of plasma and serum samples.

Key Benefits for Stakeholders:

• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.

Major Key Players of the Market:

F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Becton Dickinson and Company, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Miltenyi Biotec GmbH, Natera Inc., Promega Corporation, Myriad Genetics, Hamilton Company, OraSure Technologies Inc., Fluidigm Corporation, Streck Inc., SeraCare, Enzo Biochem Inc., Epigenomics AG, Veridex LLC

Rare Biomarkers Specimen Collection And Stabilization Market 2024 Key Insights:

• The rare biomarkers specimen collection and stabilization market size is expected to see rapid growth in the next few years. It will grow to $47.59 billion in 2028 at a compound annual growth rate (CAGR) of 10.4%.
• Increasing Prevalence Of Cancer Is Driving The Growth Of The Rare Bio Markers Specimen Collection And Stabilization
• Innovative Automated Pre-Analytical Platform Revolutionizes Biomarker Specimen Collection And Stabilization
• North America was the largest region in the rare biomarkers specimen collection and stabilization market in 2023

We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/Customise?id=15913&type=smp

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.